AR041964A1 - Vacuna de vhc que comprende un polinucleotido - Google Patents

Vacuna de vhc que comprende un polinucleotido

Info

Publication number
AR041964A1
AR041964A1 ARP030104193A ARP030104193A AR041964A1 AR 041964 A1 AR041964 A1 AR 041964A1 AR P030104193 A ARP030104193 A AR P030104193A AR P030104193 A ARP030104193 A AR P030104193A AR 041964 A1 AR041964 A1 AR 041964A1
Authority
AR
Argentina
Prior art keywords
hcv
vaccine
proteins
polynucleotide
hcv vaccine
Prior art date
Application number
ARP030104193A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR041964A1 publication Critical patent/AR041964A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ARP030104193A 2002-11-15 2003-11-13 Vacuna de vhc que comprende un polinucleotido AR041964A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine

Publications (1)

Publication Number Publication Date
AR041964A1 true AR041964A1 (es) 2005-06-01

Family

ID=9947928

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104193A AR041964A1 (es) 2002-11-15 2003-11-13 Vacuna de vhc que comprende un polinucleotido

Country Status (21)

Country Link
US (4) US20060135451A1 (https=)
EP (2) EP1560844A1 (https=)
JP (2) JP2006524181A (https=)
KR (2) KR20050085009A (https=)
CN (2) CN1738834A (https=)
AR (1) AR041964A1 (https=)
AU (2) AU2003288072A1 (https=)
BR (2) BR0316291A (https=)
CA (2) CA2504715A1 (https=)
CO (1) CO5700833A2 (https=)
GB (1) GB0226722D0 (https=)
IS (2) IS7830A (https=)
MA (2) MA27700A1 (https=)
MX (2) MXPA05005203A (https=)
NO (2) NO20052136L (https=)
NZ (2) NZ539998A (https=)
PL (2) PL376967A1 (https=)
RU (2) RU2323744C2 (https=)
TW (1) TW200502246A (https=)
WO (2) WO2004046175A1 (https=)
ZA (2) ZA200503802B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CN102614510A (zh) 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
EP1981537B1 (en) * 2006-01-04 2015-08-26 GlaxoSmithKline Biologicals S.A. HCV E1E2 MF59-adjuvanted protein plus HCV E1E2 encoding alphavirus vector for eliciting HCV-specific T cells.
ATE556136T1 (de) * 2006-03-09 2012-05-15 Transgene Sa Nichtstrukturelles hcv-fusionsprotein
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
US9439959B2 (en) 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
RU2370776C2 (ru) * 2007-11-08 2009-10-20 Общество с ограниченной ответственностью "Диагностические Центры "Алкор Био" Набор антигенов для раздельного выявления антител к структурным и неструктурным белкам вируса гепатита с
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
JP2011529077A (ja) * 2008-07-24 2011-12-01 アデュロ バイオテック Ｃ型肝炎の治療のための組成物および方法
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
CA2901501C (en) 2013-02-21 2023-03-07 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
CN119504957B (zh) * 2025-01-16 2025-04-25 中山大学 一种佐剂及其在制备疫苗中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
NZ227011A (en) * 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
CA2070952A1 (en) * 1991-06-11 1992-12-12 Makoto Seki Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
DE69533167D1 (de) * 1994-10-05 2004-07-22 Apollon Inc Impfstoffe gegen den hepatitis b und c virus
AU5924396A (en) * 1995-05-22 1996-12-11 Bionova Corporation Compositions and methods for the diagnosis of, and vaccinati on against, hepatitis c virus (hcv)
AU717542B2 (en) * 1996-06-11 2000-03-30 Merck & Co., Inc. Synthetic hepatitis C genes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
WO2001004149A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis c virus proteins
CA2389206C (en) * 1999-10-27 2011-01-04 Chiron Corporation Activation of hcv-specific t cells
CA2390082C (en) * 1999-11-24 2010-06-29 Chiron Corporation Novel hcv non-structural polypeptide
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
RU2005113691A (ru) 2006-01-27
BR0316244A (pt) 2005-10-04
RU2363492C2 (ru) 2009-08-10
ZA200503802B (en) 2006-08-30
NO20052149D0 (no) 2005-05-02
MXPA05005202A (es) 2006-01-27
IS7831A (is) 2005-04-28
CO5700833A2 (es) 2006-11-30
US20060135451A1 (en) 2006-06-22
JP2006524181A (ja) 2006-10-26
BR0316291A (pt) 2005-10-11
KR20050085009A (ko) 2005-08-29
JP2006518331A (ja) 2006-08-10
AU2003288072A1 (en) 2004-06-15
PL376967A1 (pl) 2006-01-23
NZ539999A (en) 2008-03-28
IS7830A (is) 2005-04-28
RU2005113692A (ru) 2006-01-27
CA2504715A1 (en) 2004-06-03
CN1738834A (zh) 2006-02-22
AU2003288084A1 (en) 2004-06-15
CN1738833A (zh) 2006-02-22
NO20052149L (no) 2005-07-11
RU2323744C2 (ru) 2008-05-10
ZA200503803B (en) 2006-08-30
US20090232847A1 (en) 2009-09-17
NO20052136D0 (no) 2005-05-02
US20090104231A1 (en) 2009-04-23
NZ539998A (en) 2008-04-30
TW200502246A (en) 2005-01-16
KR20050085010A (ko) 2005-08-29
US20060246090A1 (en) 2006-11-02
GB0226722D0 (en) 2002-12-24
MA27700A1 (fr) 2006-01-02
MXPA05005203A (es) 2006-01-27
WO2004046176A1 (en) 2004-06-03
EP1560845A1 (en) 2005-08-10
WO2004046175A1 (en) 2004-06-03
MA27699A1 (fr) 2006-01-02
NO20052136L (no) 2005-07-11
CA2504654A1 (en) 2004-06-03
PL376882A1 (pl) 2006-01-09
EP1560844A1 (en) 2005-08-10

Similar Documents

Publication Publication Date Title
AR041964A1 (es) Vacuna de vhc que comprende un polinucleotido
RU2541784C2 (ru) Лиофилизированная композиция для индукции иммунного ответа на флавивирус, композиция и способ для ее получения
JP5642672B2 (ja) 弱毒化ペスチウイルス
US8784839B2 (en) Attenuated live vaccines
ATE473750T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion
ES2337893T3 (es) Vacuna del virus del nilo occidental.
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
DE602005026545D1 (de) Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz
EA200401405A1 (ru) Модифицированный осповакцинный вирус анкара для вакцинации новорожденных
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
Yang et al. Type I Interferons Triggered through the Toll-Like Receptor 3–TRIF Pathway Control Coxsackievirus A16 Infection in Young Mice
AU2013339846B2 (en) Chimeric vaccine antigens against hepatitis C virus
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
TW200509964A (en) VP1 of foot-and-mouth disease virus
Hill et al. The Cellular Immune Response
WO2025075887A3 (en) Compositions and methods for preventing or treating hepatitis c viral infections
Yeong Jeong et al. Analysis of Hepatitis C Virus using Data mining algorithm-Apriori, Decision tree
AR035809A1 (es) Cromosomas artificiales que comprenden secuencias de ehv
Yang et al. Type I interferons triggered through the TLR3-TRIF pathway control
Cohen MEANWHILE, RESEARCHERS studying Omi
AR050451A1 (es) Vectores vivos recombinantes y su uso en composiciones farmaceuticas contra el virus de la hepatitis c

Legal Events

Date Code Title Description
FB Suspension of granting procedure